Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in)

NCT03616821 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03616821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03616821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
August 7, 2018
Completion date
October 23, 2023
Enrollment
242 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

ibd, ulcerative colitis